Physician profile
Kaushal Parikh
NPI 1710231006
$55,364.19
in general payments reported to CMS, 2019-2025
24 companies · $14K in 2025
The $14K reported for 2025 was more than what 83% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $9,288 · 2021: $11K · 2022: $4,376 · 2023: $5,287 · 2024: $12K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Honoraria: $5,275 · Travel and Lodging: $806 · Food and Beverage: $350 · Education: $56.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,308.50 |
| Honoraria | $5,274.89 |
| Travel and Lodging | $805.61 |
| Food and Beverage | $350.36 |
| Education | $56.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,236.36 | 2020-2025 | Tagrisso, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $6,120.00 | 2024 | Alunbrig |
| Jazz Pharmaceuticals INC. | $4,291.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $3,948.50 | 2021-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $3,369.46 | 2024 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $3,339.51 | 2020-2021 | |
| Emd Serono, INC. | $3,325.00 | 2025 | |
| Immunitybio, INC. | $2,934.89 | 2025 | |
| Beigene, Ltd. | $1,650.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,567.43 | 2020-2023 | Keytruda |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,400.00 | 2021 | |
| Janssen Biotech, INC. | $1,383.67 | 2021-2025 | Rybrevant |
| Pfizer INC. | $1,047.47 | 2020-2022 | |
| Genentech USA, INC. | $126.78 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.23 | 2021-2022 | |
| Genentech, INC. | $38.48 | 2023 | Rozlytrek, Alecensa, Gavreto |
| Abbvie INC. | $16.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2021 | |
| Lilly USA, LLC | $11.60 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaushal Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.